Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

FDA places recall on Medtronic guidewires

The FDA issued a Class I recall on Medtronic guidewires used in PCIs and in the placement of left ventricular leads for cardiac rhythm devices.

Low infant weight increases risk of cardiac cath complications

Cardiac catheterization becomes more risky with lower infant birth weights, according to a study published in the Nov. 1 issue of Catheterization and Cardiovascular Interventions. The risk is significantly higher in infants weighing less than 2 kilograms.

Thumbnail

TAVR takes spotlight at TCT.13

A quarter century ago, stents were on the periphery as planners for the first Transcatheter Cardiovascular Therapeutics (TCT) conference put together their inaugural program. Now third-generation stents share the stage with transcatheter aortic valve replacement devices.

FDA recalls transseptal sheath kit

The FDA has issued a Class 1 recall of the TorFlex Transseptal Guiding Sheath Kit, a device used in cardiac catheterization procedures.

Neovasc Reducer achieves primary endpoint in Cosira trial, significantly improving functional capabilities in patients with refractory angina

Neovasc Inc. (TSXV: NVC) today reported topline results for its COSIRA trial assessing the efficacy and safety of the Neovasc ReducerTM, a novel percutaneous device for the treatment of refractory angina. The data shows that the Reducer achieved its primary endpoint, significantly improving the symptoms and functioning of patients disabled by previously untreatable refractory angina. The COSIRA trial also confirmed that the Reducer is safe and well-tolerated, with no reports of device-related serious adverse events. The safety and efficacy data from the randomized, controlled COSIRA trial is consistent with results seen in previous non-randomized pilot studies of the Reducer.

Memorial and Heart Institute partner to advance cardiovascular care in East Texas

Memorial is pleased to announce the formation of a unique partnership with one of the area’s most well known centers for cardiovascular care – The Heart Institute of East Texas.

Vascular intervention: BIOTRONIK announces CE mark for PK Papyrus covered coronary stent for acute coronary artery perforation

BIOTRONIK announced today that the PK Papyrus covered coronary stent system has received CE mark for the treatment of acute coronary artery perforation.

Feds investigating ticagrelor’s pivotal trial

The U.S. Department of Justice (DoJ) is investigating the PLATO clinical trial, Astra Zeneca announced in a financial report.

Displaying 1777 - 1784 of 2712

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.